Discover and read the best of Twitter Threads about #OncFellows
Most recents (1)
1/9 #TumorBoardTuesday Friday Case Wrap Up
🚨Special Friday Edition of #TBT🚨
This week, mgmt of #Pancreatic neuroendo tumors (pNET), led by @nanudasmd. We discussed SOC, role of IO, & brand🆕 💊. Buckle up! We captured the discussion in this moment:
twitter.com/i/events/14995…
🚨Special Friday Edition of #TBT🚨
This week, mgmt of #Pancreatic neuroendo tumors (pNET), led by @nanudasmd. We discussed SOC, role of IO, & brand🆕 💊. Buckle up! We captured the discussion in this moment:
twitter.com/i/events/14995…
2/9 #TumorBoardTuesday Friday Case🎀
Take🏠messages:
We discussed #pNET:
✅Well diff= sens to cape/tem; high% of MGMT methylation -but not predictive of response
✅Tx dictated by disease extent
✅NOT all NETs are ➕ on dotatate! If they are, ☢️PRRT option- but may use late line
Take🏠messages:
We discussed #pNET:
✅Well diff= sens to cape/tem; high% of MGMT methylation -but not predictive of response
✅Tx dictated by disease extent
✅NOT all NETs are ➕ on dotatate! If they are, ☢️PRRT option- but may use late line
2.5/9 #TumorBoardTuesday Friday Case🎀
Take 🏠 messages continued:
✅Mixed track record of IO, despite TMB increase s/p TMZ. Higher prolif rate = better IO response
✅New: belzutifan (HIF-2a inhibitor) w activity in pNET!
✅Each pt is different- 💊 customized to pt situation
Take 🏠 messages continued:
✅Mixed track record of IO, despite TMB increase s/p TMZ. Higher prolif rate = better IO response
✅New: belzutifan (HIF-2a inhibitor) w activity in pNET!
✅Each pt is different- 💊 customized to pt situation
